Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Pamplona Capital Management has agreed to acquire Parexel International (Nasdaq: PRXL), a Boston-area contract drug research organization, for approximately $5 billion (including debt). The $88.10 per share price represents around a 5% premium to yesterday's closing price, but nearly a 28% premium to where the stock was trading in May before the first reports of a sale process emerged.
- Why it matters: This is one of the rare cases where private equity beat out strategics on a multi-billion dollar deal, with both LabCorp and ICON reportedly having submitted bids. Let alone against an Ireland-based company like ICON, which can build sorts of tax advantages into its bid. It's also just the latest example of activist investor success, as groups like Starboard Value had been agitating for a sale.
- Bottom line: "Parexel has just under 20,000 employees and made $605 million in revenue in the March quarter, according to its financials. But has been in the process of slimming down, as the CRO has had several rounds of job cuts since it dialed down its 2016 outlook in 2015. Those include 850 jobs announced 2015, in order to save about $20 million to $30 million a year from 2016, plus 1,100 to 1,200 worldwide announced just a few months ago, amid the buyout rumors." — Ben Adams, FierceBiotech